These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32859168)

  • 1. Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.
    Yanagihashi M; Okamoto R; Morioka H; Sawada M; Matsumoto S; Ikeda T; Kano O
    BMC Neurol; 2020 Aug; 20(1):319. PubMed ID: 32859168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.
    Gilhus NE; Hong Y
    Eur J Neurol; 2018 Dec; 25(12):1402-1409. PubMed ID: 30133097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
    Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
    JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis and myasthenic syndrome.
    Antozzi C
    Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary vasospasm secondary to hypercholinergic crisis: an iatrogenic cause of acute myocardial infarction in myasthenia gravis.
    Comerci G; Buffon A; Biondi-Zoccai GG; Ramazzotti V; Romagnoli E; Savino M; Rebuzzi AG; Biasucci LM; Loperfido F; Crea F
    Int J Cardiol; 2005 Sep; 103(3):335-7. PubMed ID: 16098399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis.
    Wegner B; Ahmed I
    Clin Neurol Neurosurg; 2002 Dec; 105(1):3-8. PubMed ID: 12445915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
    Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
    J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion-Related Acute Lung Injury After IVIG for Myasthenic Crisis.
    Reddy DR; Guru PK; Blessing MM; Stubbs JR; Rabinstein AA; Wijdicks EF
    Neurocrit Care; 2015 Oct; 23(2):259-61. PubMed ID: 25678454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
    Nakane S
    Rinsho Shinkeigaku; 2013; 53(11):1309-11. PubMed ID: 24291970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New diagnosis myasthenia gravis and preeclampsia in late pregnancy.
    Ozcan J; Balson IF; Dennis AT
    BMJ Case Rep; 2015 Feb; 2015():. PubMed ID: 25721832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyshidrotic eczema associated with the use of IVIg.
    Kotan D; Erdem T; Acar BA; Boluk A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary spastic angina induced by anticholinesterase medication for myasthenia gravis--a case report.
    Suzuki M; Yoshii T; Ohtsuka T; Sasaki O; Hara Y; Okura T; Shigematsu Y; Hamada M; Hiwada K
    Angiology; 2000 Dec; 51(12):1031-4. PubMed ID: 11132996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
    Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of IVIG-Induced Aseptic Chemical Meningitis.
    Patel A; Potu KC; Sturm T
    S D Med; 2017 Mar; 70(3):119-121. PubMed ID: 28813773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose intravenous immunoglobulin therapy in myasthenia gravis: a case report.
    Chu CC; Huang CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Mar; 57(3):232-5. PubMed ID: 8935232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.
    Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Wang N; Zhu KY; Brenner T; Laub O; Souroujon MC
    J Neuroimmunol; 2008 Feb; 194(1-2):89-96. PubMed ID: 18178258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.